Heron Therapeutics (HRTX) FCF Margin (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly FCF Margin came in at 6.24% in Q2 2026, up 2353.0% on a YoY basis from 0.25% in Q2 2025, and down 12.2% quarter-over-quarter from 5.56% in Q1 2026.
Powered by 
Analysis
Heron Therapeutics (HRTX) FCF Margin (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has reported FCF Margin for 12 consecutive years, with 6.24% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin rose 2353.0% year-over-year to 6.24%; the trailing twelve-month figure through Jun 2026 stood at 8.03% (up 1170.0% YoY), and the FY2025 full-year result was 18.02%, down 122.0% from the prior year.
- FCF Margin slipped to 6.24% in Q2 2026 per HRTX's latest filing, from 5.56% in the prior quarter.
- Across five years, FCF Margin topped out at 8.96% in Q3 2024 and bottomed at 191.77% in Q1 2022.
- Historically, FCF Margin has averaged 50.21% across 5 years, with a median of 28.61% in 2024.
- The sharpest annual moves came in 2022 and 2024: FCF Margin jumped 17822 bps in 2022, then plunged 3689 bps in 2024.
- Over 5 years, FCF Margin stood at 126.38% in 2022, then soared by 105 bps to 6.44% in 2023, then plunged by 573 bps to 30.45% in 2024, then grew by 26 bps to 22.63% in 2025, then soared by 72 bps to 6.24% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 6.24%, 5.56%, and 22.63% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 14.91% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -22.35% |
| 10 | Heron Therapeutics | 64.55 Mn | 21.89 Mn | 26.09 Mn | -6.24% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6.24% |
| Mar 31, 2026 | -5.56% |
| Dec 31, 2025 | -22.63% |
| Sep 30, 2025 | 3.48% |
| Jun 30, 2025 | -29.77% |
| Mar 31, 2025 | -23.08% |
| Dec 31, 2024 | -30.45% |
| Sep 30, 2024 | 8.96% |
| Jun 30, 2024 | -12.78% |
| Mar 31, 2024 | -27.45% |
| Dec 31, 2023 | 6.44% |
| Sep 30, 2023 | -31.72% |
| Jun 30, 2023 | -86.40% |
| Mar 31, 2023 | -84.84% |
| Dec 31, 2022 | -126.38% |
| Sep 30, 2022 | -139.74% |
| Jun 30, 2022 | -103.85% |
| Mar 31, 2022 | -191.77% |
| Dec 31, 2021 | -221.00% |
| Sep 30, 2021 | -235.46% |